SEC Form 4 · accession 0000885590-15-000054
Bausch Health Companies Inc. · BHC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anne Clem Whitaker
Officer — EVP, Company Group Chairman
Period of report
May 13, 2015
Accepted (ET)
Jun 24, 2015 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885590
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1,F2 | May 13, 2015 | A | 112,455 | $0.00 | A | 119,955 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This number represents the maximum number of common shares ("Common Shares") of Valeant Pharmaceuticals International, Inc. ("Valeant") that can be paid out in settlement of performance-based Restricted Share Units ("PSUs"), subject to performance based vesting criteria. See note (2).
- F2The PSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $213.42 (i.e., at 10% each vesting RSU earns one Common Share and at 30% each vesting RSU earns three Common Shares) on each of three measurement dates: 25% may vest on February 13, 2018, 50% on May 13, 2018 and 25% on August 13, 2018 with early vesting possible at higher TSR levels.